Trial Profile

EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-dR5 CAR-T cell therapy (Primary) ; Anti-EGFRvIII CAR T cell therapy (Primary) ; Anti-NY-ESO-1 CAR-T cell therapy-Shenzhen BinDeBio (Primary) ; Mesothelin-CAR-T-cell-therapy-Shenzhen-BinDeBio (Primary) ; Cyclophosphamide; Fludarabine
Indications Gastric cancer; Glioblastoma; Glioma; Gliosarcoma; Liver cancer; Oesophageal cancer
Focus Adverse reactions
Sponsors Shenzhen BinDeBio

Most Recent Events

03 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
03 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 May 2021.
10 Jul 2019 Planned initiation date changed from 15 May 2019 to 1 Sep 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com